PMH1 The Risk of Metabolic Disorders in Patients Treated with Asenapine or Olanzapine: A Real World Data Study Conducted in Italy and Spain  by Maina, G. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A453
patient’s involvement and better health outcomes. Improving service development 
and access to health advice with care experience are other adjuvant interventions. 
So patient’s participation is a key better care plan.
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In 2008, Public Procurement Law (PPL) was amended to implement and regulate 
e-Procurement in Turkey. Non-private, public purchaser hospitals are obliged to 
enter tender results of their medical device purchases into e-procurement system 
(EPS) to be eligible for a reimbursement by the Social Security Institution (SSI) in 
Turkey. Objectives of this research are to examine the impact of the EPS that is 
currently being used for medical device purchases in Turkey since 2011; and to 
investigate how the system is being used to define ceiling prices for reimbursement, 
concurrently assessing the quality and quantity of data uploaded by hospitals. EPS 
data is downloaded on a GMDN basis from Turkish National Database for Medical 
Devices, (TITUBB) which is an e-catalogue system that was launched to provide bar-
code level product registration, search and the e-procurement results. In accordance 
with the objectives, assessment is conducted on more than ten GMDNs and results 
are utilized to see the effect of EPS on pricing, comparing the prices on officially 
published SSI positive lists. Our study shows that a lowest price detected on EPS 
could be set as the reimbursement price, as was the case for the product; aortic stent 
graft, contralateral limb, where a defined SSI positive list price was reduced after 
determination of a lower price on EPS, on account of  a mispriced tender record. 
An extrapolation while searching out the reimbursement prices is needed instead 
of SSI’s calculations based on merely a retrospective and detection of lowest price 
practice. Effectiveness of this policy depends on resolving the weaknesses of EPS 
data in terms of quality and quantity; a misdated tender or a mispriced product 
could be a ground for an erroneous price setting and tenders that are not recorded 
at all or deferred might lead to incomplete EPS data to define reimbursement prices.
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Objectives: Second-generation antipsychotic drugs, knows as Atypical 
Antipsychotics, have a better tolerability than conventional antipsychotics but it 
has reported that its usage lead to a substantial weight gain, an increase risk of 
dyslipidemia and type 2 diabetes mellitus. In this article authors assessed the risk 
of metabolic adverse events associated with Asenapine in comparison with those 
associated with Olanzapine by studying real world data. MethOds: The study was 
a retrospective analysis based on data extracted from Italian and Spanish Cegedim 
Stategic Data Longitudinal Patient Data databases. Patients were divided in two 
cohorts (Asenapine and Olanzapine) according to the inclusion criteria and data 
from these patients were analyzed starting from 2009 up to 2013. Diabetes and 
dyslipidemia registrations have been searched in order to assess the risk of develop-
ing metabolic adverse events. Results: The retrospective analysis showed a lower 
risk of developing type 2 diabetes and dyslipidemia associated with Asenapine 
treatment in comparison with Olanzapine. Scenario analyses supported the robust-
ness of the results. cOnclusiOns: Asenapine is associated with a lower risk of 
metabolic adverse events than Olanzapine, demonstrating a better safety profile 
with regard to metabolic effects.
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Objectives: The purpose of this study was to apply a systematic review of the 
literature to evaluate the diagnostic effectiveness of the Phosphorylated tau p181 
for the Alzheimer’s disease dementia. MethOds: A systematic literature review 
was used to evaluate the effectiveness of of the Phosphorylated tau p181 for the 
Alzheimer’s disease dementia. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to independently evaluate the quality of the 
ten studies. The literature review covered from October 27, 1946 to October 22, 2013, 
and eight domestic databases including KoreaMed and foreign databases includ-
ing Ovid-MEDLINE, EMBASE, and Cochrane Library were used. Results: A total of 
9studies (9 diagnostic evaluation studies) were identified to evaluate Phosphorylated 
tau. Theeffectiveness of this test was evaluated based on diagnostic accuracy. The 
diagnostic accuracy for identifying AD of ELISA was high (pooled sensitivity, 0.843 
(95% CI 0.818-0.867); pooled specificity, 0.799 (95% CI 0.768-0.828); summary receiver 
operating characteristic area under the curve 0.9082±0.0236. Primary criteria for 
inclusion were valid studies on (i) patients with mild cognitive impairment with 
confirmed or suspected AD and non-AD dementia, and (ii) assessment of tau levels 
using appropriate comparative tests. cOnclusiOns: Evaluated CSF Phosphorylated 
tau levels are of potential utility in the differential diagnosis of AD versus non-AD 
dementias and healthy controls.
of options and requirements by country. The evaluation of market access options for 
OD-HOM can ease market access and reimbursement and influence international 
launch sequences of innovative orphan drugs.
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Objectives: Despite the growing interest in observational studies, there is any 
defined regulatory process unlike clinical trials, which have a defined one. Currently, 
international observational studies have to deal with each county regulatory process 
that means to face times and costs very heterogeneous and not regulated yet by 
the EU. Here we report the experience of MediData in international observational 
study conduct. MethOds: The start-up process in 7 countries was analyzed as for 
regulatory process in terms of time and costs. Results: In Europe the faster regu-
latory process takes 12 weeks (Turkey) and the slowest one takes almost twice as 
long (Italy 24 weeks), while in the USA they spend almost 16 weeks to conclude the 
whole process. Usually times and costs have an inverse relationship, but the observa-
tional studies analyzed shows that the second cheaper country is Turkey, that comes 
after France where the process is free. Another example of this variety is the case of 
Spain and France in the same duration of the process have a difference of spending 
of 12000 € . cOnclusiOns: These duration and spending really differentiated 
have a huge impact on the observational study conduction. Especially at the inter-
national level, we might run into sponsored studies which could be conducted in 
countries with cheaper or faster regulation processes, with the real risk of a selection 
bias of the sites and, therefore, a very partial collection of data. Inevitably, the result 
will be unrepresentative epidemiological data. It’s very important to have a pan-Euro-
pean regulation that allows the observational study conduction in an homogenous 
and aligned way and also to have complete and representative epidemiological data.
PHP295
access To orPHan druGs in france: THe case of siklos for THe 
TreaTmenT of sickle cell syndrome before THe council of sTaTe
Murteira S.1, El Hammi E.2, Kornfeld A.3, Toumi M.4
1Lundbeck Japan KK, Tokoyo, Japan, 2Evidenz, Tunis, Tunisia, 3Creativ-Ceutical, Paris, France, 
4University of Marseille, Marseille, France
bAckgROund: Hydroxycarbamid is an antineoplastic molecule commercialized 
since 1968 in France under the name Hydrea®. In the absence of an alternative 
licensed drug for the treatment of Sickle Cell Syndrome (SCS), Hydrea® has been rou-
tinely used off-label for over 15 years in this indication. In 2007, Siklos® became the 
first licensed orphan drug indicated in the symptomatic treatment of SCS. However, 
during the pricing and reimbursement procedures, the French Transparency 
Committee decided to compare Siklos® to Hydrea® and as such Siklos® was evalu-
ated as bringing a weak additional benefit (ASMR IV) which had a major impact on 
the price given by the French Economic Committee on Health Care Products (CEPS). 
The manufacturer of Siklos® entered in litigation with the CEPS and after a long 
legal procedure, the French Council of State issued two orders by way of interlocu-
tory procedures suspending the decision of the drug price setting and determining 
the minimal threshold under which Health Authorities could not set the price of 
this drug. discussiOn: The negative assessment of the French HTA could have set 
a precedent for future evaluations of orphan or pediatric medicines issued from 
drug repurposing. These decisions are unique in the history of the Council of State’s 
jurisprudence on several aspects: it was an unprecedented case where a CEPS deci-
sion is overturned by the Council of State and the first time that a judicial decision 
provides guidance on the price level for a pharmaceutical drug in France. This case 
law has also the consequence to enlarge the criteria taken into account by the CEPS 
in new drug price setting, especially for orphan drugs. cOnclusiOn: Siklos® case 
law provided a new legal ground that is in contradiction with available regulation 
and practice and opens the way for future legal challenges to the CEPS decisions.
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Objective: Patient’s involvement in their health care is important to improve qual-
ity, efficacy and better patient care. It is a strategy to achieve improved health 
outcomes and lower costs. A main objective of the discussion is focused on “how 
to inform, encourage and educate the patient to participate in their health care 
decisions?” The purpose of the discussion also centered on the various patients 
focused interventions required to improve the health care outcomes by patient’s 
participation. bAckgROund: All patients want the information about the disease 
and complications they have, but not all want to involve in decision making. Most of 
the patients preferred to leave the final decision on doctors/clinicians. Engagement 
of patients in health care and decision making would improve the health outcomes 
and lowering the cost of therapy or treatment. discussiOn: Health care is a com-
plicated system to patients; they struggle to understand their medical conditions 
and services. All patients must have to know about basic health information and 
treatment options. This would be possible by encouraging patient’s to play an active 
role in their health care that could improve health outcomes, efficiency and quality. 
Patient’s participation and engagement are based on patient activation which refers 
to understanding, ability, health literacy and willingness of patient to manage his or 
her health and care. Patients can participate at different levels as direct care or their 
preference in treatment plan and/or in policy making for future recommendations. 
Patient focused interventions are discussed as companion to patient’s participation 
or engagement. Improvement in health literacy, patient safety, improvement in self 
care and clinical decision making are four primary interventions which promote the 
